Investigational and not approved by the FDA. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Apraglutide

Investigational

GLP-2 receptor agonist

Evidence score

56/ 100

Moderate evidence

A real evidence base, with gaps

Regulatory standing. In clinical trials, not yet approved
Limited human data. Some human data exists, not conclusive
Registered human trials. 10 registered studies on ClinicalTrials.gov, most advanced Phase 3
No sources. Nothing cited to verify

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Apraglutide is an investigational synthetic peptide analog of glucagon-like peptide-2 (GLP-2), a gut hormone that supports the growth and function of the intestinal lining. It was designed to last longer in the body than native GLP-2, and it is being studied mainly for short bowel syndrome with intestinal failure and for graft-versus-host disease affecting the gut.

What the evidence shows

Automatic summaryLimited human data

Apraglutide is not FDA-approved; about 10 registered human trials exist, reaching Phase 3, and early and late-stage studies have reported effects on intestinal fluid absorption and reduced need for parenteral support. Whether it is safe and effective enough for approval has not been established by regulators.

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

10registered studies

Phase 3most advanced phase

6completed (sample)

1recruiting (sample)

Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)

Phase 2CompletedNCT04964986

Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)

Phase 2TerminatedNCT05415410

Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.

Phase 3Active Not RecruitingNCT05018286

Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas

Phase 2WithdrawnNCT03417765

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

27papers referencing Apraglutide

Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.

J Pharmacol Exp Ther2020

Apraglutide, a novel glucagon-like peptide-2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo-controlled, randomized phase 2 trial.

JPEN J Parenter Enteral Nutr2022

Novel Long-Acting GLP-2 Analogue, FE 203799 (Apraglutide), Enhances Adaptation and Linear Intestinal Growth in a Neonatal Piglet Model of Short Bowel Syndrome with Total Resection of the Ileum.

JPEN J Parenter Enteral Nutr2019

Therapeutic Potential of GLP-2 Analogs in Gastrointestinal Disorders: Current Knowledge, Nutritional Aspects, and Future Perspectives.

Curr Nutr Rep2022

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.